Alercell adds Harvard researcher Ina Dreschnack to advisory board

Alercell appointed Ina Dreschnack, MSc, a Harvard graduate researcher in neuroscience and psychopathology, to its Advisory Board on June 10, 2026. The company said her translational research background will help shape development of the LENA Platform and its therapeutic recommendation engine, LENA-Rx.

Why it matters: - Alercell is trying to move its LENA Platform from diagnostic detection toward LENA-Rx, a therapeutic recommendation engine. - Dreschnack brings translational research experience in neuroscience, molecular biology and pilot study design that Alercell says fits that roadmap. - The hire also adds academic and public-health experience as Alercell pursues regulatory and fundraising goals.

What happened: - Alercell appointed Ina Dreschnack, MSc, to its Advisory Board on June 10, 2026. - Dreschnack is a molecular biologist and graduate researcher at Harvard University. - Dreschnack is pursuing a master’s in psychology with a concentration in neuroscience and psychopathology. - Alercell is based in Bozeman, Montana.

The details: - Dreschnack is a co-author of multiple peer-reviewed publications on mechanism-based therapeutics in neurological and neuropsychiatric disease. - Alercell said her advisory role will focus on disease pathomechanism, translational research methodology and clinical pilot study design. - Dreschnack’s research background includes work on extracellular vesicles, stem cell therapies and glial dysfunction. - Her publication record includes four peer-reviewed papers spanning Alzheimer’s disease, amyotrophic lateral sclerosis, psoriatic arthritis and idiopathic facial paralysis. - Those papers appeared in Medical Research Archives and BMC Neurology. - Dreschnack holds an MSc in Molecular Biology from the University of Tirana. - Dreschnack also has a Bachelor of Science in Biology from the University of Tirana. - Her prior roles included specialist positions at Albania’s Ministry of Health and the Institute of Public Health in Tirana. - Alercell’s flagship product is the LENA Platform, short for Leukemia Epigenetic Navigational Algorithm. - The platform uses the company’s Kinetic Information Theory framework and a qMethyl-48 panel covering 48 methylation loci. - LENA Platform components include LENA Code, LENA Clock, LENA Score and LENA-Rx. - Alercell said analytical validation covered an analytic subcohort of 139,568 subjects from a curated cohort of more than 199,000 electronic medical records. - The company is pursuing a two-rail regulatory strategy under Montana SB 535. - That strategy includes laboratory-developed test deployment through CLIA enforcement discretion and an FDA De Novo pathway for LENA-Rx. - Alercell is also in active Series A fundraising.

Between the lines: - The appointment signals Alercell wants advisory input that bridges basic biology, clinical translation and regulatory planning. - The focus on neuroscience and translational medicine suggests the company is looking for scientific talent outside traditional diagnostics to support a future therapeutic layer. - Dreschnack’s background in public health may also help Alercell think through access and policy considerations as it expands.

What’s next: - Alercell said Dreschnack will inform the scientific roadmap as the LENA Platform advances. - The company is working toward LENA-Rx while continuing validation and regulatory work for its diagnostic platform. - Alercell is also seeking capital as it advances its clinical-stage program.

The bottom line: - Alercell is building an advisory bench aimed at turning a diagnostic product into a broader translational medicine platform.